Company · Analysis · 31 Oct 2026
Indo-Bangla Pharmaceuticals: revenue of BDT 184.2m in FY2025 against BDT 866.1m in FY2020, a qualified audit with a going-concern paragraph, and 9M FY2026 profit of BDT 2.8m
The Barishal-based tablet and capsule maker reported net losses of BDT 41.0m in FY2024 and BDT 36.8m in FY2025. Its auditor qualified the FY2025 accounts on four bases and reported a material uncertainty on going concern. Nine-month FY2026 revenue was BDT 134.8m, against BDT 76.9m a year earlier.
Indo-Bangla Pharmaceuticals PLC (IBP) makes and sells human-health medicines, excluding antibiotics, from a single factory at College Road, Barishal. The business traces to Indo-Pak Pharmaceutical Works, founded in 1954; it was privatised in 1982, incorporated as a private limited company on 18-Jun-2014, converted to a…